Advertisement

Tamoxifen Tablets

[04 August 2014]

Products Affected - Description

Tamoxifen tablets, Mylan
10 mg, 60 count (NDC 00378-0144-91)
10 mg, 500 count (NDC 00378-0144-05)
20 mg, 30 count (NDC 00378-0274-93)
20 mg, 100 count (NDC 00378-0274-01)

Reason for the Shortage

  • Teva and Mylan could not provide a reason for the shortage.
  • Actavis could not provide a reason for the shortage.

Available Products

Tamoxifen tablets, Actavis
10 mg, 60 count (NDC 00591-2472-60)
10 mg, 180 count (NDC 00591-2472-18)
20 mg, 30 count (NDC 00591-2473-30)
20 mg, 90 count (NDC 00591-2473-19)

Tamoxifen tablets, Teva
10 mg, 60 count (NDC 00093-0784-06)
10 mg, 180 count (NDC 00093-0784-86)
10 mg, 500 count (NDC 00093-0784-05)
10 mg, 1000 count (NDC 00093-0784-10)
20 mg, 30 count (NDC 00093-0782-56)
20 mg, 100 count (NDC 00093-0782-01)
20 mg, 500 count (NDC 00093-0782-05)
20 mg, 1000 count (NDC 00093-0782-10)

Estimated Resupply Dates

Mylan has all temporarily discontinued all tamoxifen tablets and the company cannot estimate a release date. 

Related Shortages

Updated

August 4, 2014; May 29, 2014; May 9, 2014; April 15, 2014; April 3, 2014; March 6, 2014; January 7, 2014, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement